Price cuts alone may not be enough to counter consumer caution and slowing category growth.

Doctors must reassert personalized nutrition advice, while food brands should highlight their better-for-you offerings.

US dietary guidelines overhaul decades of low-fat advice and target added sugar.

Nearly 4 in 10 (38%) US parents consider themselves supporters of the Make America Healthy Again (MAHA) movement, according to a recent KFF/The Washington Post survey. MAHA supporters and non-supporters hold distinct views on the importance and safety of vaccines and other children’s health issues. Pharma and food marketers should encourage open dialogue around the concerns expressed by MAHA proponents. Marketers need to reach parents who are MAHA supporters with transparent, evidence-based messaging—not lectures—on food and drug safety.

PepsiCo is scrambling to overhaul its portfolio in response to pressure from the “Make America Healthy Again” movement and activist investor Elliott Investment Management. CPG giants like PepsiCo are having a difficult time staying current with the rapidly shifting food landscape. Food trends are emerging faster than ever, while few last the test of time—making it challenging for brands to determine where to focus their resources. As the trend cycle speeds up, CPGs must be nimble to avoid losing share. Selling off non-core assets and splitting up could help reduce organizational bloat, but companies must also prioritize innovation to ensure they can stay relevant as demand shifts.

Food companies look to profit from consumers’ protein fixation: Demand for healthier products—and pressure from the MAHA movement—is pushing manufacturers to embrace “better for you” options.

RFK Jr.’s MAHA vision receives support in Indiana: Gov. Mike Braun issued nine executive orders aligning with Kennedy’s chronic illness agenda. But cuts to Medicaid funding could prevent these initiatives from having their intended effect.

RFK to lead Trump’s Make America Healthy Again commission: Trump’s executive order outlines policies and actions that could impact medication access for children, how quickly drugs get to market, and how federal health agencies conduct research.